Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy - Takeaways - MDSpire

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy

  • By

  • Zichao You

  • Li Jiang

  • Ying-rui Liu

  • Ming Ming Yang

  • June 23, 2026

  • 0 min

Share

  • 1

    Diabetic macular edema (DME) is a leading cause of visual impairment in adults with diabetes mellitus.

  • 2

    Intravitreal anti-VEGF therapies are the first-line treatment for DME, but 30-50% of patients show inadequate responses.

  • 3

    Multimodal imaging techniques like OCT, OCTA, and UWF-FA help identify structural and microvascular changes in DME.

  • 4

    The review categorizes imaging biomarkers into disease activity markers and predictors of visual prognosis.

  • 5

    DME can be classified into five clinical phenotypes based on distinct biomarker profiles for tailored treatment.

Original Source(s)

Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy

  • by Zichao You, Li Jiang, Ying-rui Liu, Ming Ming Yang

  • June 23, 2026

Related Content

The difference in scotopic and photopic pupil responses: a potential indicator for long-term glycemic management

Utilizing Machine Learning to Identify Risk Factors for Diabetic Microvascular Complications and Develop a Predictive Model with Gradient Boosting Decision Trees

Steroid Strategies in Diabetic Macular Edema